GS 4059

Drug Profile

GS 4059

Alternative Names: GS-4059; ONO-4059

Latest Information Update: 20 Feb 2017

Price : $50

At a glance

  • Originator Ono Pharmaceutical
  • Developer Gilead Sciences; Ono Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia
  • Phase I B cell lymphoma; Rheumatoid arthritis
  • Preclinical Systemic lupus erythematosus

Most Recent Events

  • 17 Mar 2017 Gilead Sciences plans a phase II trial for Rheumatoid arthritis (Combination therapy) (Gilead Sciences 10-K, February 2017)
  • 03 Dec 2016 Efficacy and adverse events data from a phase I trial in Chronic lymphocytic leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
  • 03 Dec 2016 Pharmacokinetics and Pharmacodynamics data from preclinical trial in Diffuse large B cell lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016) (3218946; 3224662)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top